Progress on inflation was "noticeably" slower last year than in 2023, and upside risks to higher price pressures remain, and therefore the U.S. central bank should adopt a cautious and gradual ...

AbbVie saw fourth-quarter sales handily beat Wall Street's projections as gains from its newer anti-inflammatory drugs helped offset declines from Humira, once its best performing asset. The drugmaker ...

Fortune magazine's annual ranking of the "world's most admired companies" - the latest of which was released this week - provides yet another object lesson in contrarian analysis. That's because ...

AbbVie Inc.'s stock rose 4% early Friday, after the drug company beat fourth-quarter earnings estimates and offered an upbeat view of 2025.